en
Pharmaceuticals
Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.
A C D E F G I L M N P R S T V X Z
Gilenya*
(fingolimod (as fingolimod hydrochloride))
Sphingosine 1-phosphate receptor modulator
*Gilenya is a registered trademark
Gleevec*
(imatinib mesylate)
Protein Kinase Inhibitor
Important information for healthcare professionals (2009)
Important information for healthcare professionals (2006)
*Gleevec is a registered trademark
Research
Novartis is one of the industry’s biggest investors in research.
ABOUT NOVARTIS
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Sandoz
Sandoz is one of the leaders in the development, manufacturing and distribution of generic pharmaceutical products.